Indivior PLC (INDV.L)
- Previous Close
1,524.00 - Open
1,500.00 - Bid --
- Ask --
- Day's Range
1,481.00 - 1,518.00 - 52 Week Range
1,125.00 - 1,938.00 - Volume
237,744 - Avg. Volume
489,631 - Market Cap (intraday)
2.053B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
1,514.00 - EPS (TTM)
0.01 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2016
- 1y Target Est
24.62
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
www.indivior.com1,164
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: INDV.L
Performance Overview: INDV.L
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDV.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDV.L
Valuation Measures
Market Cap
2.07B
Enterprise Value
1.96B
Trailing P/E
1.90k
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.46
Price/Book (mrq)
--
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
29.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.18%
Return on Assets (ttm)
8.73%
Return on Equity (ttm)
7.84%
Revenue (ttm)
1.09B
Net Income Avi to Common (ttm)
2M
Diluted EPS (ttm)
0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
410M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-61.25M